beyond reason
해열진통제로 알려진 아스피린(일반적인 용량은 500mg)
저용량 아스피린(하루에 75~100mg)을 장기복용하면 암예방효과가 있다는 네이처 리뷰논문
참고) 아스피린 경구복용후 30-40분만에 혈중농도가 최대치로 올라가고 100mg이하 소량일때 혈중반감기는 15-20분에 불과함.
항혈소판 효과는 아스피린과 접촉한 혈소판의 cox1은 비가역적으로 아세틸화되어 오랫동안 기능이 억제되기 때문에 소량으로 충분함. 반감기는 300~650 mg 일 경우 3.1 - 3.2시간, 1g일 경우 6시간, 2g일 경우 9시간
그림에서 보는 바와같이 저용량 아스피린은 암세포의 혈관신생증가를 억제하고 세포증식을 억제하여 세포사멸을 촉진함.
The role of aspirin in cancer prevention
Abstract
Clinical guidelines for prophylactic aspirin use currently only consider the cardiovascular benefits of aspirin, weighed against the potential harm from aspirin-induced bleeding. Daily aspirin use has been convincingly shown to reduce the risk of colorectal cancer and recurrence of adenomatous polyps, but in average-risk populations, these benefits alone do not outweigh harms from aspirin-induced bleeding.
Recently published secondary analyses of cardiovascular trials provide the first randomized evidence that daily aspirin use may also reduce the incidence of all cancers combined, even at low doses (75–100 mg daily).
This Review considers the general mechanism of action that defines aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) as a class, the specific advantages of aspirin over other NSAIDs for prophylactic use, the current evidence concerning the main health outcomes affected by aspirin use, and the hypothesis that inhibition of platelet activation may mediate both the cardioprotective and cancer-preventive effects of lowdose aspirin. It also considers how even a 10% reduction in overall cancer incidence beginning during the first 10 years of treatment could tip the balance of benefits and risks favourably in average-risk populations.
Thun, M. J. et al. Nat. Rev. Clin. Oncol. 9, 259–267 (2012); published online 3 April 2012; doi:10.1038/nrclinonc.2011.199